uniQure (NASDAQ:QURE) Given New $9.00 Price Target at The Goldman Sachs Group

by · The Cerbat Gem

uniQure (NASDAQ:QURE – Free Report) had its price objective lowered by The Goldman Sachs Group from $10.00 to $9.00 in a report released on Wednesday morning,Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the biotechnology company’s stock.

A number of other equities research analysts also recently commented on the company. Raymond James reaffirmed an “outperform” rating and issued a $20.00 price objective on shares of uniQure in a research report on Thursday, October 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $28.00 price objective on shares of uniQure in a research note on Wednesday. Royal Bank of Canada cut their price objective on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Wednesday. StockNews.com raised shares of uniQure to a “sell” rating in a research report on Thursday, October 17th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of uniQure in a research note on Tuesday, August 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $17.00.

Read Our Latest Stock Report on QURE

uniQure Price Performance

NASDAQ:QURE opened at $7.79 on Wednesday. uniQure has a 12-month low of $3.73 and a 12-month high of $11.35. The firm has a market cap of $379.71 million, a price-to-earnings ratio of -1.57 and a beta of 0.90. The company’s 50-day moving average is $5.77 and its two-hundred day moving average is $5.83. The company has a current ratio of 6.51, a quick ratio of 7.36 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QURE – Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The business had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. Research analysts expect that uniQure will post -4.1 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. abrdn plc grew its stake in uniQure by 381.7% during the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after buying an additional 1,528,581 shares during the period. Vanguard Group Inc. boosted its position in uniQure by 11.4% during the 1st quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock worth $5,577,000 after purchasing an additional 109,740 shares during the period. Privium Fund Management B.V. increased its holdings in uniQure by 16.3% in the 3rd quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after purchasing an additional 104,500 shares in the last quarter. BNP Paribas Financial Markets raised its position in uniQure by 4.3% in the first quarter. BNP Paribas Financial Markets now owns 736,724 shares of the biotechnology company’s stock valued at $3,831,000 after purchasing an additional 30,054 shares during the period. Finally, Acadian Asset Management LLC lifted its stake in shares of uniQure by 133.1% during the first quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock worth $3,189,000 after purchasing an additional 350,291 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

(Get Free Report)

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

Featured Articles